09:00
Open and welcome from the chairperson
Optimising the commercial General Counsel and legal team in the life sciences industry today
- How has the role of general counsel developed? What is now expected?
- How can the legal team add value to the business?
- Influence from within: the general counsel’s role at an executive level
- Gerry Kennedy UK General Counsel, Lonza
09:15
Developing products: clinical trials in the modern world
- An overview of the commercial, reimbursement and supply chain considerations – where are the key markers?
- What is the role of digital technology and social media when developing products?
- In today’s marketplace, what are the competition restrictions and at what point should you assess these?
- Rhianon Ebsworth Senior Corporate Counsel, Novo Nordisk
10:00
MORNING REFRESHMENTS
10:20
BREAKOUT SESSIONS
Please choose one of the following sessions.
A1 Bribery and corruption
- The Bribery Act: what are the lessons learnt from other industries so far?
- Auditing of suppliers, subsidiaries and acquired companies
- SFO investigations – what’s the process and what should you have in place?
- Top tips for in-house lawyers
- Robert Barrington Executive Director, Transparency International
A2 Avoiding common pitfalls when developing medical devices and pharmaceutical products
INTERACTIVE SESSION
- What to consider when diversifying from drugs to medical devices
- Where medical technology (including apps, wearable devices and ‘smart’ products) fits in the legal landscape
- How research, clinical trials and risk analysis can minimise the threat of litigation
- Dorothy Flower Partner, RPC
- Peter Rudd-Clarke Senior Associate, RPC
11:05
BREAKOUT SESSIONS
Please choose one of the following sessions.
B1 Harmonising data privacy laws and your obligation to be transparent
- How can you do both simultaneously?
- A global view: getting data privacy right in multiple jurisdictions
- Handling data enquiries internally – what are the resources you need?
- How should you prepare for the new EU Data Protection Regulation? What is the impact of privacy by design?
- Jonathan Sellors Legal Counsel, UK Biobank
- Andrew Dyson Partner, DLA Piper
B2 The legal team’s role in managing PR during and after an investigation or enforcement
- How should you and your team prepare for post-litigation media enquiries? What are the questions they might ask?
- What should you be doing to support the PR team on a day-to-day basis?
- Richard Elsen Co-founder, Byfield Consultancy
11:50
Generic and brand name producers: two sides of the same coin
- A walkthrough of the differing product lifecycles
- The differing business models and business needs – where are they the same, where are they different? How does this impact the legal function?
- What are the key areas of legal support for generic and originator companies?
- Maiken Keson-Brookes SVP and General Counsel, FORUM Pharmaceuticals
- Suzanne Smith Executive Director, Legal, ACTAVIS
12:40
LUNCH
13:30
INTERVIEW: “A day in the life of a life sciences Head of Legal”
Join us for the interview as our expert asks our Head of Legal what it’s like working in the life sciences industry.
- What are the day-to-day tasks?
- What are the biggest challenges?
- How do you get the most out of your team?
Click here to submit your question to the interviewee.
- Edward Rees Head of Legal, Norgine
14:00
Maximising opportunities: managing mergers and acquisitions
- Due diligence: who do you need to involve and at what stage to ensure the strategy succeeds?
- Avoiding the chaos: what are the top risks associated with mergers, acquisitions and product acquisitions and how do you handle them?
- A triumph: how do you ensure successful integration across the new business?
- Brian Sheridan Vice President, Corporate Legal Affairs & General Counsel, Sorin Group
- Charles Cook Partner, DLA Piper
14:45
Effectively managing collaborations
- Starting off on the right foot: outlining the collaboration
- What do you need to think about when drafting the contracts? Be aware of exit strategies/dealing with disputes – joint steering committees – what tools should you have ready for a smooth exit?
- Maximising co-marketing, co-promotion and R&D agreements
- Nicole Reichman General Counsel, OTSUKA PHARMACEUTICAL EUROPE
- Anthony Kenny Assistant General Counsel, GSK
- Amandine Pascal Legal Director (Research & Development), Ipsen
- Bonella Ramsay Head of Intellectual Property, DLA Piper
15:30
AFTERNOON REFRESHMENTS
15:50
Preparing for and dealing with product liability claims
- The checklist: how to prepare for potential adversity at the earliest stages of a product lifecycle
- What are the key milestones during the process of facing a product liability claim?
- Controlling negative association – the dangers to look out for and the steps to mitigate damage to your brand
- Louisa Caswell Partner, Addleshaw Goddard
- Sonia Campbell Partner, Addleshaw Goddard
16:35
INTERACTIVE ROUNDTABLES
Country-focus roundtables on the key life sciences markets across the world. Join our experts as they highlight the challenges and recent developments in different jurisdictions, the impact on your business and the ways to take advantage of the opportunities and work around the challenges.
China
- Katherine Wang Partner, Ropes & Gray
- Arthur Mok Managing Partner, Ropes & Gray
- Geoffrey Lin Partner, Ropes & Gray
India
- Khushboo Baxi Head, Pharma & Life Sciences Practice, Nishith Desai
- Dr.Milind Antani Partner and Head, Pharma & Life Sciences & Social Sector Practice Group, Nishith Desai
17 :30
Closing comments
Followed by a canapé and drinks reception